Company Profile
Soleno Therapeutics Stock Price, News & Catalysts
- Ticker:
- SLNO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
53.01 USD (+0.04%)
Close
Last updated: May 15, 2026
2.76B USD
Market cap
Why the stock is moving
Current closing-price context is not available for SLNO.
Company overview
Prader-Willi Syndrome Focus
Soleno Therapeutics develops and commercializes therapies for rare diseases. Its initial franchise addresses hyperphagia, the persistent and potentially life-threatening hunger associated with Prader-Willi syndrome.
VYKAT XR
VYKAT XR is a once-daily extended-release formulation of diazoxide choline approved in the United States for hyperphagia in adults and children age four and older with Prader-Willi syndrome. It is the company’s first commercial product.
International Expansion
Soleno has begun building a commercial patient and prescriber base in the United States and has submitted a European marketing application. The company plans to use the U.S. launch infrastructure and disease-community relationships to support expansion into additional territories.
Future catalysts
- Soleno’s catalysts are DCCR in Prader-Willi syndrome and the next regulatory / commercialization steps around that program. The stock is still driven by whether the rare-disease opportunity can keep advancing.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Soleno Therapeutics (SLNO)?
Soleno Therapeutics (SLNO) most recently closed at 53.01 USD, a +0.04% move versus the previous session.
What is the market cap of Soleno Therapeutics (SLNO)?
Soleno Therapeutics currently has a market capitalization of 2.76B USD on BioPharmSignal.
What does Soleno Therapeutics do?
Prader-Willi Syndrome Focus Soleno Therapeutics develops and commercializes therapies for rare diseases. Its initial franchise addresses hyperphagia, the persistent and potentially life-threatening hunger associated with Prader-Willi syndrome. VYKAT XR VYKAT XR is a once-daily extended-release formulation of diazoxide choline approved in the United States...
On which exchange is SLNO stock listed?
Soleno Therapeutics (SLNO) is associated with NASDAQ, United States, Biopharma.
What is Prader-Willi?
Soleno’s catalysts are DCCR in Prader-Willi syndrome and the next regulatory / commercialization steps around that program.
Which conditions is Soleno Therapeutics targeting with Prader-Willi?
Soleno Therapeutics is associated with rare disease based on its company overview and current catalyst commentary.
How does Soleno Therapeutics describe recent progress with Prader-Willi?
Soleno’s catalysts are DCCR in Prader-Willi syndrome and the next regulatory / commercialization steps around that program.
What is Syndrome?
Prader-Willi Syndrome Focus Soleno Therapeutics develops and commercializes therapies for rare diseases.